These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 32525068

  • 41. Regulation of androgen receptor expression by Z-isochaihulactone mediated by the JNK signaling pathway and might be related to cytotoxicity in prostate cancer.
    Liu PY, Lin SZ, Sheu JJ, Lin CT, Lin PC, Chou YW, Huang MH, Chiou TW, Harn HJ.
    Prostate; 2013 Apr; 73(5):531-41. PubMed ID: 23038474
    [Abstract] [Full Text] [Related]

  • 42. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S, Nayak S, Fernandes G, Barai RS, Menon S, Chaudhari UK, Kholkute SD, Sachdeva G.
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [Abstract] [Full Text] [Related]

  • 43. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.
    Yu P, Duan X, Cheng Y, Liu C, Chen Y, Liu W, Yin B, Wang X, Tao Z.
    Int J Mol Med; 2017 Nov; 40(5):1426-1434. PubMed ID: 28901378
    [Abstract] [Full Text] [Related]

  • 44. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.
    Jang YG, Go RE, Hwang KA, Choi KC.
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279
    [Abstract] [Full Text] [Related]

  • 45. A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo.
    Zhang Y, Shaik AA, Xing C, Chai Y, Li L, Zhang J, Zhang W, Kim SH, Lü J, Jiang C.
    Invest New Drugs; 2012 Oct; 30(5):1820-9. PubMed ID: 21870073
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
    Attardi BJ, Burgenson J, Hild SA, Reel JR.
    Mol Cell Endocrinol; 2004 Jul 30; 222(1-2):121-32. PubMed ID: 15249132
    [Abstract] [Full Text] [Related]

  • 50. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T.
    Cancer Res; 2009 Oct 15; 69(20):8141-9. PubMed ID: 19808968
    [Abstract] [Full Text] [Related]

  • 51. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays.
    Kim HJ, Park YI, Dong MS.
    Toxicol In Vitro; 2006 Oct 15; 20(7):1159-67. PubMed ID: 16621434
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies.
    Hsieh TC, Lu X, Guo J, Xiong W, Kunicki J, Darzynkiewicz Z, Wu JM.
    Int J Oncol; 2002 Apr 15; 20(4):681-9. PubMed ID: 11894110
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
    Tsui KH, Chang YL, Feng TH, Hou CP, Lin YH, Yang PS, Lee BW, Juang HH.
    Prostate; 2018 Mar 15; 78(4):242-249. PubMed ID: 29164633
    [Abstract] [Full Text] [Related]

  • 56. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
    Ben Jemaa A, Sallami S, Céraline J, Oueslati R.
    Cell Biol Int; 2013 May 15; 37(5):464-70. PubMed ID: 23418075
    [Abstract] [Full Text] [Related]

  • 57. MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer.
    Andolfi C, Bartolini C, Morales E, Gündoğdu B, Puhr M, Guzman J, Wach S, Taubert H, Aigner A, Eder IE, Handle F, Culig Z.
    Endocrinology; 2024 Aug 27; 165(10):. PubMed ID: 39253786
    [Abstract] [Full Text] [Related]

  • 58. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.
    Prostate; 2011 Sep 27; 71(12):1344-56. PubMed ID: 21308717
    [Abstract] [Full Text] [Related]

  • 59. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T, Okabe S, Seimiya H.
    Mol Pharmacol; 2010 Nov 27; 78(5):846-54. PubMed ID: 20709811
    [Abstract] [Full Text] [Related]

  • 60. PYK2 via S6K1 regulates the function of androgen receptors and the growth of prostate cancer cells.
    Hsiao YH, Huang YT, Hung CY, Kuo TC, Luo FJ, Yuan TC.
    Endocr Relat Cancer; 2016 Aug 27; 23(8):651-63. PubMed ID: 27492635
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.